News | Atrial Fibrillation | June 30, 2023

Women with Common Heart Rhythm Disorder Have Faster Cognitive Decline Than Men

Women with atrial fibrillation progress more rapidly to cognitive impairment and dementia than men with the heart rhythm condition, according to research presented today at ACNAP 2023

Getty Images


June 30, 2023 — Women with atrial fibrillation progress more rapidly to cognitive impairment and dementia than men with the heart rhythm condition, according to research presented today at ACNAP 2023, a scientific congress of the European Society of Cardiology (ESC)1 and published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 

“Symptoms of atrial fibrillation in women are often ignored by healthcare providers or attributed to stress or anxiety so it can go undiagnosed for long period of time, while men are more likely to be diagnosed and treated quickly,” said study author Dr. Kathryn Wood of Emory University, Atlanta, US. “Being undiagnosed means not receiving oral anticoagulant medication to prevent blood clots and strokescaused by atrial fibrillation. These women may be having clots that go to small blood vessels in their brain, causing them to lose brain function gradually and develop cognitive impairment.” 

“ESC Guidelines for the care of patients with atrial fibrillation recommend oral anticoagulants for both women and men,” continued Dr. Wood.2 “However, we know that women are less likely to receive these medications than men.3,4 This is another reason why women may have small silent strokes that go unrecognized and damage brain tissue leading to cognitive impairment.” 

Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million people worldwide.2 People with this condition have a five-fold increased risk of stroke compared with their healthy peers. Women have more atrial fibrillation symptoms than men and worse outcomes from the disorder, with a higher risk of death and more disabling strokes.2,5,6 

Dementia is more common in women than men.7 Atrial fibrillation is associated with a higher risk for cognitive impairment and dementia, possibly because the condition is linked with a more than two-fold risk of silent strokes.8 The accumulation of silent strokes and the associated brain injuries over time may contribute to cognitive impairment. Stroke prevention with oral anticoagulant drugs is the main priority in the management of atrial fibrillation and may reduce the risk of dementia. 

This was the first longitudinal study to use multicenter data to examine sex differences in the prevalence of cognitive disease in patients with atrial fibrillation and the trajectory to dementia. The study included 43,630 participants of the National Alzheimer’s Coordinating Center (NACC) cohort which has enrolled adults from the US general population since 1984. Of those, 4,593 (11%) had atrial fibrillation at baseline and 39,037 (89%) did not. The average age was 78.5 years and 46% were women. To be included in this study, participants were required to have at least three annual clinic visits during which they took neuropsychological tests and were categorized as normal cognition, mild cognitive impairment (MCI) or dementia. 

The researchers analyzed the associations between 1) atrial fibrillation and baseline cognitive diagnosis; and 2) atrial fibrillation and time to progression in cognitive diagnosis. The analyses were adjusted for factors that could influence the relationships including age, sex, race, education, body mass index, smoking, depression, hypertension, diabetes, high cholesterol, heart failure, stroke, and sleep apnea. Men and women with atrial fibrillation were compared to those without the condition and differences by gender were examined. 

Women with atrial fibrillation were three times more likely to have MCI and dementia at baseline compared to women without atrial fibrillation, with odds ratios of 3.43 (MCI) and 3.00 (dementia). The odds ratios for men were 1.73 and 1.60, respectively, but neither association was statistically significant in men. 

During a median follow-up of four years, 30% of participants progressed to a worse stage of cognitive impairment and 21% developed dementia. Women with atrial fibrillation had a higher risk of progressing to a worse stage of cognitive impairment compared to women without atrial fibrillation, with a hazard ratio (HR) of 1.21. Regarding progression to each stage, compared to women without atrial fibrillation, women with the condition were more likely to transition from normal cognition to MCI (HR 1.17) and from MCI to vascular dementia (HR 2.57). The associations between atrial fibrillation and more rapid cognition decline were not statistically significant in men. 

Dr. Wood said: “The analyses indicate stronger associations between atrial fibrillation and declining cognitive function in women compared with men. Establishing ways to identify atrial fibrillation patients at the highest risk of cognitive decline and stroke will inform future interventions to prevent or slow the progression to cognitive impairment and dementia.” 

For more information: www.escardio.org 

 

References and notes 

1The abstract ‘Sex differences in atrial fibrillation and progression to dementia’ will be presented during the session ‘Research aimed to advance patient well being’ which takes place on 23 June at 10:45 CEST in the ACNAP Scientific Corner. 

2Hindricks G, Potpara T, Nikolaos Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498. 

3Yong CM, Tremmel JA, Lansberg MG, et al. Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation. J Am Heart Assoc. 2020;9:e015689. 

4Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR) PINNACLE Registry. J Am Heart Assoc. 2017;6:e005801. 

5Blum S, Muff C, Aeschbacher S, et al. Prospective assessment of sex-related differences in symptom status and health perception among patients with atrial fibrillation. J Am Heart Assoc. 2017;6:e005401. 

6Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018;20:1565–1565ao. 

7Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement. 2013;9:63–75.e2. 

8Dagres N, Chao TF, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 2018;20:1399–1421.


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now